English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Angina which is refractory to conventional medical therapy and revascularisation with bypass surgery and/or percutaneous coronary intervention is extremely challenging to manage with limited treatment options and a pressing need to establish effective therapy. Lipoprotein(a) [Lp(a)], a genetically determined form of LDL-cholesterol, is an independent cardiovascular risk factor which is felt to increase risk by promoting thrombosis; enhancing intimal lipoprotein deposition, and by potentially affecting myocardial perfusion, microvascular function, plasma viscosity and endothelial function. Lipoprotein apheresis is currently the most effective treatment available for raised Lp(a). Increasing evidence suggests that aggressive Lp(a) reduction may improve cardiovascular outcomes, although much more prospective research is required to confirm this.

Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)